论文部分内容阅读
目的 探讨复发难治性恶性脑膜瘤的抗血管生成治疗疗效。方法 回顾性分析复发难治性恶性脑膜瘤使用抗血管生成药物贝伐珠单抗治疗的3例病例临床资料。结果 3例患者使用贝伐珠单抗后MRI均可见到T2 FLAIR相水肿范围缩小,2例患者增强病灶稳定,1例患者缩小。3例患者临床症状均有缓解,无疾病进展时间分别为2.5、5、7个月。结论 贝伐珠单抗使用于常规治疗后复发难治性的恶性脑膜瘤大部分患者可获得临床症状缓解,影像上肿瘤控制,但控制时间有限,难达到临床治愈。
Objective To investigate the efficacy of antiangiogenic therapy for relapsed and refractory malignant meningioma. Methods The clinical data of 3 cases of relapsed and refractory malignant meningioma treated with anti-angiogenic drug bevacizumab were retrospectively analyzed. Results The extent of edema in the T2 FLAIR phase was reduced in all three patients after bevacizumab use. The stability of the lesions was enhanced in 2 patients and was reduced in 1 patient. The clinical symptoms of 3 patients were all relieved. No disease progression time was 2.5, 5 and 7 months respectively. Conclusion Bevacizumab can be used in the treatment of relapsed and refractory malignant meningioma after routine treatment. Most patients can obtain clinical symptom remission and imaging tumor control, but the control time is limited, and it is difficult to achieve clinical cure.